Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E7.48 EPS (ttm)13.42 Insider Own0.10% Shs Outstand43.50M Perf Week-8.71%
Market Cap4.36B Forward P/E12.39 EPS next Y8.10 Insider Trans-76.08% Shs Float42.95M Perf Month-17.24%
Income587.40M PEG- EPS next Q2.77 Inst Own- Short Float8.55% Perf Quarter-12.13%
Sales1.63B P/S2.68 EPS this Y22.60% Inst Trans-0.11% Short Ratio9.71 Perf Half Y-21.02%
Book/sh64.55 P/B1.55 EPS next Y-13.03% ROA18.00% Target Price126.00 Perf Year-10.56%
Cash/sh32.55 P/C3.08 EPS next 5Y-9.50% ROE22.50% 52W Range100.06 - 130.00 Perf YTD-7.86%
Dividend- P/FCF7.35 EPS past 5Y32.40% ROI19.00% 52W High-22.82% Beta1.09
Dividend %- Quick Ratio6.00 Sales past 5Y7.80% Gross Margin87.80% 52W Low0.28% ATR3.18
Employees860 Current Ratio6.40 Sales Q/Q-17.90% Oper. Margin46.20% RSI (14)24.12 Volatility3.48% 2.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.40% Profit Margin36.20% Rel Volume1.37 Prev Close100.65
ShortableYes LT Debt/Eq0.09 EarningsFeb 27 BMO Payout0.00% Avg Volume378.54K Price100.34
Recom- SMA20-12.50% SMA50-13.89% SMA200-15.20% Volume518,891 Change-0.31%
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
Dec-27-17Reiterated Wedbush Outperform $213 → $232
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Apr-17-19 10:52PM  United Therapeutics Issues Statement In Response To Meritless Lawsuit PR Newswire -5.93%
Apr-12-19 01:16PM  Is United Therapeutics Corporation's (NASDAQ:UTHR) Liquidity Good Enough? Simply Wall St.
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 10:06AM  United Therapeutics Discontinues PAH Drug After Study Fails Zacks
09:30AM  Company News For Apr 9, 2019 Zacks
Apr-08-19 02:52PM  United Therapeutics drops drug prospect after failed trial American City Business Journals -5.70%
12:48PM  Stocks making the biggest moves midday: Snap, GE, Boeing, AMC & more CNBC
06:00AM  United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint PR Newswire
Apr-01-19 08:00AM  Report: Exploring Fundamental Drivers Behind Coeur Mining, Owens & Minor, Telenav, Cedar Realty Trust, j2 Global, and United Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-29-19 09:30AM  United Therapeutics (UTHR) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-28-19 03:10PM  Supernus reports mixed ADHD drug trial results. So why isn't it worried? American City Business Journals
Mar-12-19 06:00AM  United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference PR Newswire
Mar-11-19 12:48PM  Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years Simply Wall St.
Mar-05-19 10:55AM  MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results Zacks Small Cap Research
Mar-04-19 06:00AM  United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference PR Newswire -5.30%
Mar-01-19 10:19PM  Edited Transcript of UTHR earnings conference call or presentation 27-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 10:16AM  United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates Zacks
Feb-27-19 03:31PM  United Therapeutics Corp (UTHR) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:25AM  Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues Zacks
06:00AM  United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results PR Newswire
Feb-26-19 05:55PM  MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:43PM  Here's Why MannKind Rocketed Higher Today Motley Fool
Feb-20-19 06:00AM  United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019 PR Newswire
Feb-13-19 10:31AM  Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks
10:00AM  Does United Therapeutics Corporations (NASDAQ:UTHR) CEO Salary Reflect Performance? Simply Wall St.
Jan-31-19 08:00PM  Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress PR Newswire
Jan-28-19 07:45AM  Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-25-19 07:38AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug Benzinga
Jan-24-19 08:00PM  United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag PR Newswire
08:00PM  Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag PR Newswire
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
Jan-08-19 09:54AM  Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares? Simply Wall St.
Dec-31-18 06:00AM  United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-17-18 10:11PM  United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-11-18 10:00AM  MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target Zacks Small Cap Research
Dec-07-18 02:22PM  Should You Be Excited About United Therapeutics Corporations (NASDAQ:UTHR) 20% Return On Equity? Simply Wall St.
Dec-03-18 06:46PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR PR Newswire
Nov-30-18 09:31AM  United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue? Zacks
Nov-29-18 04:30PM  Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma PR Newswire
Nov-27-18 05:00AM  Analysts: Why United Therapeutics has had a streak of licensing deals American City Business Journals
Nov-26-18 10:00AM  CORV: Topline Growth Accelerating Zacks Small Cap Research
Nov-23-18 07:25AM  Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-21-18 11:21AM  Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal Zacks
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-16-18 09:11AM  Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22% Zacks
Nov-15-18 12:33PM  Why Arena Pharmaceuticals Stock Is Soaring Today InvestorPlace
11:05AM  Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today Motley Fool
07:33AM  United Therapeutics to develop, sell Arena Pharma's hypertension treatment Reuters
07:00AM  Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag PR Newswire
Nov-12-18 06:00AM  CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants PR Newswire
Nov-06-18 04:00PM  Correvio Reports Third Quarter 2018 Financial Results CNW Group
09:25AM  Edited Transcript of UTHR earnings conference call or presentation 31-Oct-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 11:14AM  United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips Zacks
06:00AM  Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Oct-31-18 02:46PM  United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.63%
07:30AM  United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates Zacks
06:20AM  United Therapeutics: 3Q Earnings Snapshot Associated Press
06:00AM  United Therapeutics Corporation Reports Third Quarter 2018 Financial Results PR Newswire
Oct-24-18 06:00AM  United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018 PR Newswire -6.72%
Oct-23-18 03:20PM  An Intrinsic Calculation For United Therapeutics Corporation (NASDAQ:UTHR) Shows Its 45.03% Undervalued Simply Wall St.
Oct-22-18 04:00AM  CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants PR Newswire
Oct-17-18 10:32AM  United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards? Zacks
Oct-16-18 05:22PM  Why MannKind Corp. Soared 16.4% Tuesday Motley Fool
06:00AM  United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement PR Newswire
06:00AM  United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement GlobeNewswire
Oct-15-18 11:38AM  AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally Zacks
Oct-11-18 09:51AM  Here's What Sent MannKind Corporation Soaring 66.4% in September Motley Fool
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Oct-08-18 09:42AM  Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland Zacks
Oct-05-18 09:30AM  UTHR vs. NBIX: Which Stock Is the Better Value Option? Zacks
09:30AM  5 Stocks Trading Near 52-Week High With More Upside in Store Zacks
Oct-02-18 12:56PM  The exec makes how much? Here are the highest CEO-employee pay ratios in the D.C. area. American City Business Journals
Sep-27-18 02:25PM  MannKind Stock History Motley Fool
Sep-26-18 03:37PM  United Therapeutics, Martine Rothblatt's daughter sued for sexual harassment American City Business Journals
Sep-24-18 09:30AM  Should Value Investors Pick United Therapeutics (UTHR) Stock? Zacks
Sep-18-18 11:18AM  United Therapeutics In-Licenses Rights to IPF Candidate Zacks
06:00AM  United Therapeutics Corporation To Host Science Day 2018 PR Newswire
Sep-17-18 06:00AM  Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate PR Newswire
Sep-14-18 03:40PM  S Spotlight On United Therapeutics Corporations (NASDAQ:UTHR) Fundamentals Simply Wall St.
Sep-13-18 03:12PM  United Therapeutics makes another real estate buy American City Business Journals
Sep-08-18 07:50PM  Is MannKind Corporation Stock a Buy? Motley Fool
07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 06:00AM  RANKED: Best Places To Work - Extra-Large Companies American City Business Journals
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool
08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
Sep-05-18 04:56PM  New Development Partnership Could Pay Off Big for MannKind Stock InvestorPlace
11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
Sep-04-18 11:27AM  Why MannKind Stock Is Skyrocketing Today InvestorPlace
10:06AM  Why MannKind Corporation Stock Is Skyrocketing Today Motley Fool
09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:54AM  United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery American City Business Journals
07:00AM  Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics CNW Group
Aug-31-18 11:51AM  United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue? Zacks
Aug-30-18 07:08AM  United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd. PR Newswire
Aug-28-18 03:45PM  CORV: US Brinavess Launch Now Reflected Zacks Small Cap Research
Aug-08-18 08:00PM  United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso PR Newswire
06:00AM  United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint PR Newswire
Aug-07-18 04:00PM  United Therapeutics Corporation To Present At 2018 Wedbush PacGrow Healthcare Conference PR Newswire
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giltner RichardDirectorApr 05Option Exercise41.145,000205,7005,000Apr 05 04:10 PM
CAUSEY CHRISTOPHERDirectorApr 04Option Exercise63.9075047,9251,725Apr 05 04:11 PM
MAHON PAUL AEVP & General CounselMar 21Option Exercise92.536,000555,18041,323Mar 22 04:11 PM
PATUSKY CHRISTOPHERDirectorMar 20Option Exercise54.775,000273,8505,000Mar 22 04:16 PM
ROTHBLATT MARTINE AChairman & CEOMar 19Option Exercise52.657,055371,4467,195Mar 20 04:03 PM
ROTHBLATT MARTINE AChairman & CEOMar 18Option Exercise52.657,055371,4467,195Mar 20 04:03 PM
Thompson Tommy GDirectorMar 18Option Exercise52.6517,100900,31520,070Mar 19 05:35 PM
CAUSEY CHRISTOPHERDirectorMar 14Option Exercise63.9075047,9251,725Mar 18 08:03 AM
MAHON PAUL AEVP & General CounselMar 07Option Exercise65.806,000394,80041,823Mar 08 04:01 PM
PATUSKY CHRISTOPHERDirectorMar 07Sale110.753,370373,2280Mar 08 04:02 PM
SULLIVAN LOUIS WDirectorMar 01Option Exercise54.771,00054,7702,370Mar 04 05:25 PM
MAHON PAUL AEVP & General CounselFeb 21Option Exercise65.806,000394,80041,613Feb 22 05:49 PM
CAUSEY CHRISTOPHERDirectorFeb 07Option Exercise63.9075047,9251,725Feb 08 04:03 PM
MAHON PAUL AEVP & General CounselFeb 07Option Exercise65.806,000394,80041,613Feb 08 04:02 PM
Thompson Tommy GDirectorFeb 05Sale117.0040046,8002,970Feb 05 04:28 PM
ROTHBLATT MARTINE AChairman & CEOJan 31Option Exercise52.657,054371,3937,194Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 31Sale115.307,054813,349140Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Sale115.847,054817,160140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Sale115.707,054816,176140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Sale115.577,054815,238140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Sale115.167,054812,359140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Sale113.957,054803,780140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Sale112.947,054796,709140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Sale113.357,054799,591140Jan 23 08:28 AM
CAUSEY CHRISTOPHERDirectorJan 18Option Exercise63.9075047,9251,725Jan 22 05:01 PM
ROTHBLATT MARTINE AChairman & CEOJan 18Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 18Sale115.157,054812,285140Jan 23 08:28 AM
MAHON PAUL AEVP & General CounselJan 17Option Exercise65.806,000394,80041,613Jan 18 04:07 PM
ROTHBLATT MARTINE AChairman & CEOJan 17Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 17Sale113.797,054802,679140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Sale113.617,054801,423140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Sale114.867,054810,200140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Sale114.847,054810,056140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 11Option Exercise52.657,054371,3937,194Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 11Sale113.597,054801,235140Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 10Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 10Sale113.597,054801,235140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Sale113.437,054800,121140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 08Option Exercise52.657,054371,3937,194Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 08Sale113.167,054798,220140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Option Exercise52.657,055371,4467,195Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Sale113.407,055800,056140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 04Option Exercise52.657,055371,4467,195Jan 07 06:38 PM
ROTHBLATT MARTINE AChairman & CEOJan 04Sale111.517,055786,719140Jan 07 06:38 PM
MAHON PAUL AEVP & General CounselJan 03Option Exercise65.806,000394,80041,613Jan 04 04:01 PM
SULLIVAN LOUIS WDirectorJan 02Option Exercise54.771,00054,7702,370Jan 03 04:02 PM
MAHON PAUL AEVP & General CounselDec 20Option Exercise65.806,000394,80041,613Dec 21 04:06 PM
Thompson Tommy GDirectorDec 11Option Exercise52.6590047,3854,270Dec 11 04:04 PM
MAHON PAUL AEVP & General CounselDec 06Option Exercise62.4810,000624,82042,613Dec 07 04:02 PM
SULLIVAN LOUIS WDirectorDec 03Option Exercise54.771,00054,7702,370Dec 04 04:04 PM
CAUSEY CHRISTOPHERDirectorNov 01Option Exercise54.7775041,0782,305Nov 02 04:08 PM
MAHON PAUL AEVP & General CounselNov 01Option Exercise61.066,000366,36041,613Nov 02 04:07 PM
MAHON PAUL AEVP & General CounselOct 18Option Exercise65.806,000394,80041,613Oct 19 04:03 PM
CAUSEY CHRISTOPHERDirectorOct 04Option Exercise54.7775041,0782,305Oct 09 08:21 AM
MAHON PAUL AEVP & General CounselOct 04Option Exercise61.066,000366,36041,613Oct 09 08:20 AM
SULLIVAN LOUIS WDirectorOct 01Option Exercise54.771,00054,7704,370Oct 02 04:11 PM
MAHON PAUL AEVP & General CounselSep 20Option Exercise61.066,000366,36041,613Sep 24 04:01 PM
CAUSEY CHRISTOPHERDirectorSep 10Sale119.0081096,3901,555Sep 10 04:05 PM
CAUSEY CHRISTOPHERDirectorSep 06Option Exercise54.7775041,0783,925Sep 07 04:15 PM
MAHON PAUL AEVP & General CounselSep 06Option Exercise61.066,000366,36041,613Sep 07 04:17 PM
CAUSEY CHRISTOPHERDirectorSep 06Sale118.0081095,5802,365Sep 07 04:15 PM
SULLIVAN LOUIS WDirectorSep 04Option Exercise54.771,00054,7704,370Sep 05 04:06 PM
MAHON PAUL AEVP & General CounselAug 16Option Exercise61.066,000366,36041,613Aug 17 04:06 PM
Giltner RichardDirectorAug 16Sale129.383,240419,1980Aug 17 04:08 PM
CAUSEY CHRISTOPHERDirectorAug 02Option Exercise54.7775041,0783,925Aug 03 04:03 PM
MAHON PAUL AEVP & General CounselAug 02Option Exercise61.066,000366,36041,613Aug 03 04:02 PM
SULLIVAN LOUIS WDirectorAug 01Option Exercise54.771,00054,7704,370Aug 02 04:05 PM
MAHON PAUL AEVP & General CounselJul 19Option Exercise61.066,000366,36041,613Jul 20 04:23 PM
PATUSKY CHRISTOPHERDirectorJul 06Option Exercise51.773,500181,1956,870Jul 09 04:02 PM
CAUSEY CHRISTOPHERDirectorJul 05Option Exercise54.7775041,0783,925Jul 06 04:06 PM
MAHON PAUL AEVP & General CounselJul 05Option Exercise61.066,000366,36041,613Jul 06 04:05 PM
SULLIVAN LOUIS WDirectorJul 02Option Exercise54.771,00054,7704,370Jul 05 04:13 PM
DWEK RAYMONDDirectorJun 29Sale113.073,240366,3530Jun 29 05:36 PM
Thompson Tommy GDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:31 PM
KURZWEIL RAYDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:25 PM
Giltner RichardDirectorJun 28Option Exercise0.003,24003,240Jun 28 07:21 PM
DWEK RAYMONDDirectorJun 28Option Exercise0.003,24003,240Jun 28 07:16 PM
PATUSKY CHRISTOPHERDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:11 PM
SULLIVAN LOUIS WDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:05 PM
CAUSEY CHRISTOPHERDirectorJun 28Option Exercise0.001,62003,175Jun 28 06:59 PM
Olian Judy D.DirectorJun 28Option Exercise0.003,24006,130Jun 28 06:52 PM
MAHON PAUL AEVP & General CounselJun 21Option Exercise61.066,000366,36041,613Jun 25 05:03 PM
CAUSEY CHRISTOPHERDirectorJun 15Option Exercise54.772,250123,2333,805Jun 19 04:07 PM
Olian Judy D.DirectorJun 12Sale112.3860067,4252,890Jun 13 04:06 PM
MAHON PAUL AEVP & General CounselJun 07Option Exercise61.066,000366,36041,613Jun 08 04:24 PM
SULLIVAN LOUIS WDirectorJun 05Option Exercise51.7715,000776,55016,750Jun 06 04:01 PM
MAHON PAUL AEVP & General CounselMay 17Option Exercise61.066,000366,36041,613May 18 04:02 PM
MAHON PAUL AEVP & General CounselMay 03Option Exercise61.066,000366,36041,613May 04 04:16 PM